– Results Underscore Need for Continued Research and Diverse Treatment Pipeline
CHICAGO, Nov. 24, 2025 /PRNewswire/ — The Alzheimer’s Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer’s disease progression. The studies tested an oral semaglutide pill for the treatment of early-stage symptomatic Alzheimer’s disease.
“While these results are not what we had hoped for, they will contribute to our understanding of this devastating and fatal disease,” said Joanne Pike, DrPH, Alzheimer’s Association president and chief executive officer. “The data from every clinical trial, regardless of outcome, is vital to accelerating our understanding of this disease and helps inform the next generation of clinical trials. We remain optimistic about the future of Alzheimer’s treatment and prevention, as the scientific landscape continues to diversify and expand.”
The company said, “While treatment with semaglutide resulted in improvement of Alzheimer’s disease-related biomarkers in both trials, this did not translate into a delay of disease progression.” The evoke and evoke+ trials were large-scale, long-term international clinical trials. More than 3,800 people ages 55-85 diagnosed with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease, (referred to as stage 3 and 4 of Alzheimer’s disease), were enrolled.
“These results will help us refine our understanding of this class of drugs,” said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer and medical affairs lead. “Though this semaglutide pill did not help against Alzheimer’s, the field will continue to investigate this class of drugs, as they may act differently. And, the Alzheimer’s Association remains a fierce leader for this type of innovative research, and we believe it’s critical to continue investigating diverse approaches to treatment and prevention.”
The Alzheimer’s treatment pipeline is robust and full of hope. An annual evaluation of the drug development pipeline published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions in early 2025, shows there are 182 active clinical trials evaluating 138 novel drugs. The Alzheimer’s Association, through its “Part the Cloud” program, provides strategic funding to advance promising investigational Alzheimer’s therapies into clinical trials. The treatment targets are varied, which is important given the growing consensus that effective treatment and prevention of Alzheimer’s is likely to be a personalized combination of multiple interventions.
For people living with early Alzheimer’s, approved treatments are available. We urge individuals to talk to their doctor about these options. Individuals can also talk to their doctor about participating in clinical trials, or visit the Alzheimer’s Association’s TrialMatch for more information.
The Association appreciates these topline results and looks forward to hearing a deeper dive into the data at the Clinical Trials in Alzheimer’s Disease (CTAD) meeting in December.
About the Alzheimer’s Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia®. Visit alz.org or call 800.272.3900.
Logo – https://mma.prnewswire.com/media/2689936/5639737/Alzheimers_Association_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/alzheimers-association-statement-on-oral-semaglutide-phase-3-topline-data-release-302624620.html
